#FORMAT=WebAnno TSV 3.2
#T_SP=webanno.custom.Referent|entity|infstat
#T_RL=webanno.custom.Coref|type|BT_webanno.custom.Referent


#Text=1 .
1-1	0-1	1	quantity	new	coref	4-11
1-2	2-3	.	_	_	_	_

#Text=Introduction
2-1	4-16	Introduction	abstract	new	_	_

#Text=Eosinophils are a subset of granulocytes mostly known for their capacity to stimulate allergic reactions and to fight parasites .
3-1	17-28	Eosinophils	abstract	new	coref	3-3[4_0]
3-2	29-32	are	_	_	_	_
3-3	33-34	a	abstract[4]	giv[4]	coref	5-17[0_4]
3-4	35-41	subset	abstract[4]	giv[4]	_	_
3-5	42-44	of	abstract[4]	giv[4]	_	_
3-6	45-57	granulocytes	abstract[4]|abstract	giv[4]|new	ana	3-10
3-7	58-64	mostly	_	_	_	_
3-8	65-70	known	_	_	_	_
3-9	71-74	for	_	_	_	_
3-10	75-80	their	abstract|abstract[7]	giv|new[7]	_	_
3-11	81-89	capacity	abstract[7]	new[7]	_	_
3-12	90-92	to	_	_	_	_
3-13	93-102	stimulate	_	_	_	_
3-14	103-111	allergic	event[8]	new[8]	_	_
3-15	112-121	reactions	event[8]	new[8]	_	_
3-16	122-125	and	_	_	_	_
3-17	126-128	to	_	_	_	_
3-18	129-134	fight	_	_	_	_
3-19	135-144	parasites	animal	new	_	_
3-20	145-146	.	_	_	_	_

#Text=Under normal conditions , these cells are relatively rare representing 1 – 3 % of total white blood cells .
4-1	147-152	Under	_	_	_	_
4-2	153-159	normal	abstract[10]	new[10]	coref	5-2[16_10]
4-3	160-170	conditions	abstract[10]	new[10]	_	_
4-4	171-172	,	_	_	_	_
4-5	173-178	these	object[11]	new[11]	coref	4-16[15_11]
4-6	179-184	cells	object[11]	new[11]	_	_
4-7	185-188	are	_	_	_	_
4-8	189-199	relatively	_	_	_	_
4-9	200-204	rare	_	_	_	_
4-10	205-217	representing	_	_	_	_
4-11	218-219	1	quantity	giv	_	_
4-12	220-221	–	_	_	_	_
4-13	222-223	3	quantity[13]	new[13]	_	_
4-14	224-225	%	quantity[13]	new[13]	_	_
4-15	226-228	of	quantity[13]	new[13]	_	_
4-16	229-234	total	quantity[13]|object[15]	new[13]|giv[15]	coref	5-35[28_15]
4-17	235-240	white	quantity[13]|object[15]	new[13]|giv[15]	_	_
4-18	241-246	blood	quantity[13]|substance|object[15]	new[13]|new|giv[15]	_	_
4-19	247-252	cells	quantity[13]|object[15]	new[13]|giv[15]	_	_
4-20	253-254	.	_	_	_	_

#Text=During certain inflammatory conditions ( i. e. , allergies , parasitic infections , autoimmune diseases ) eosinophils can rapidly increase , due to both de novo generation from bone marrow precursors and proliferation of tissue-resident cells , infiltrating inflamed tissues , including tumors .
5-1	255-261	During	_	_	_	_
5-2	262-269	certain	abstract[16]	giv[16]	_	_
5-3	270-282	inflammatory	abstract[16]	giv[16]	_	_
5-4	283-293	conditions	abstract[16]	giv[16]	_	_
5-5	294-295	(	_	_	_	_
5-6	296-298	i.	_	_	_	_
5-7	299-301	e.	_	_	_	_
5-8	302-303	,	_	_	_	_
5-9	304-313	allergies	abstract	new	_	_
5-10	314-315	,	_	_	_	_
5-11	316-325	parasitic	event[18]	new[18]	_	_
5-12	326-336	infections	event[18]	new[18]	_	_
5-13	337-338	,	_	_	_	_
5-14	339-349	autoimmune	abstract[19]	new[19]	_	_
5-15	350-358	diseases	abstract[19]	new[19]	_	_
5-16	359-360	)	_	_	_	_
5-17	361-372	eosinophils	substance	giv	coref	7-4
5-18	373-376	can	_	_	_	_
5-19	377-384	rapidly	_	_	_	_
5-20	385-393	increase	_	_	_	_
5-21	394-395	,	_	_	_	_
5-22	396-399	due	_	_	_	_
5-23	400-402	to	_	_	_	_
5-24	403-407	both	abstract[23]	new[23]	_	_
5-25	408-410	de	object|abstract[23]	new|new[23]	_	_
5-26	411-415	novo	object|abstract[23]	new|new[23]	_	_
5-27	416-426	generation	abstract[23]	new[23]	_	_
5-28	427-431	from	abstract[23]	new[23]	_	_
5-29	432-436	bone	abstract[23]|object|object[26]	new[23]|new|new[26]	coref|coref	17-22|17-22
5-30	437-443	marrow	abstract[23]|animal|object[26]	new[23]|new|new[26]	coref	17-21[140_0]
5-31	444-454	precursors	abstract[23]|object[26]	new[23]|new[26]	_	_
5-32	455-458	and	abstract[23]	new[23]	_	_
5-33	459-472	proliferation	abstract[23]|event[27]	new[23]|new[27]	_	_
5-34	473-475	of	abstract[23]|event[27]	new[23]|new[27]	_	_
5-35	476-491	tissue-resident	abstract[23]|event[27]|object[28]	new[23]|new[27]|giv[28]	coref	9-43[70_28]
5-36	492-497	cells	abstract[23]|event[27]|object[28]	new[23]|new[27]|giv[28]	_	_
5-37	498-499	,	_	_	_	_
5-38	500-512	infiltrating	_	_	_	_
5-39	513-521	inflamed	object[29]	new[29]	coref	9-57[0_29]
5-40	522-529	tissues	object[29]	new[29]	_	_
5-41	530-531	,	_	_	_	_
5-42	532-541	including	_	_	_	_
5-43	542-548	tumors	object	new	coref	6-8[33_0]
5-44	549-550	.	_	_	_	_

#Text=Tumor-associated tissue eosinophilia has been described in various solid tumors although its prognostic value in clinical oncology remains controversial .
6-1	551-567	Tumor-associated	abstract[32]	new[32]	ana	6-12[0_32]
6-2	568-574	tissue	object|abstract[32]	new|new[32]	_	_
6-3	575-587	eosinophilia	abstract[32]	new[32]	_	_
6-4	588-591	has	_	_	_	_
6-5	592-596	been	_	_	_	_
6-6	597-606	described	_	_	_	_
6-7	607-609	in	_	_	_	_
6-8	610-617	various	object[33]	giv[33]	_	_
6-9	618-623	solid	object[33]	giv[33]	_	_
6-10	624-630	tumors	object[33]	giv[33]	_	_
6-11	631-639	although	_	_	_	_
6-12	640-643	its	abstract|abstract[35]	giv|new[35]	_	_
6-13	644-654	prognostic	abstract[35]	new[35]	_	_
6-14	655-660	value	abstract[35]	new[35]	_	_
6-15	661-663	in	abstract[35]	new[35]	_	_
6-16	664-672	clinical	abstract[35]|abstract[36]	new[35]|new[36]	_	_
6-17	673-681	oncology	abstract[35]|abstract[36]	new[35]|new[36]	_	_
6-18	682-689	remains	_	_	_	_
6-19	690-703	controversial	_	_	_	_
6-20	704-705	.	_	_	_	_

#Text=In vivo , eosinophils were shown to exert a protective role inhibiting tumor growth in mouse models of melanoma , colorectal cancer , hepatocellular carcinoma , and inducible fibrosarcoma .
7-1	706-708	In	_	_	_	_
7-2	709-713	vivo	abstract	new	_	_
7-3	714-715	,	_	_	_	_
7-4	716-727	eosinophils	substance	giv	coref	8-3
7-5	728-732	were	_	_	_	_
7-6	733-738	shown	_	_	_	_
7-7	739-741	to	_	_	_	_
7-8	742-747	exert	_	_	_	_
7-9	748-749	a	abstract[39]	new[39]	coref	21-21[170_39]
7-10	750-760	protective	abstract[39]	new[39]	_	_
7-11	761-765	role	abstract[39]	new[39]	_	_
7-12	766-776	inhibiting	_	_	_	_
7-13	777-782	tumor	abstract|abstract[41]	new|new[41]	coref|coref|coref|coref	14-20|19-7[150_41]|14-20|19-7[150_41]
7-14	783-789	growth	abstract[41]	new[41]	_	_
7-15	790-792	in	_	_	_	_
7-16	793-798	mouse	animal|abstract[43]	new|new[43]	_	_
7-17	799-805	models	abstract[43]	new[43]	_	_
7-18	806-808	of	abstract[43]	new[43]	_	_
7-19	809-817	melanoma	abstract[43]|abstract	new[43]|new	coref	16-17
7-20	818-819	,	abstract[43]	new[43]	_	_
7-21	820-830	colorectal	abstract[43]|abstract[45]	new[43]|new[45]	coref	15-18[0_45]
7-22	831-837	cancer	abstract[43]|abstract[45]	new[43]|new[45]	_	_
7-23	838-839	,	abstract[43]	new[43]	_	_
7-24	840-854	hepatocellular	abstract[43]|abstract|object[47]	new[43]|new|new[47]	coref|coref|coref|coref	10-11[0_47]|20-17|10-11[0_47]|20-17
7-25	855-864	carcinoma	abstract[43]|object[47]	new[43]|new[47]	_	_
7-26	865-866	,	abstract[43]	new[43]	_	_
7-27	867-870	and	abstract[43]	new[43]	_	_
7-28	871-880	inducible	abstract[43]|abstract[48]	new[43]|new[48]	_	_
7-29	881-893	fibrosarcoma	abstract[43]|abstract[48]	new[43]|new[48]	_	_
7-30	894-895	.	_	_	_	_

#Text=Furthermore , eosinophils infiltration in the lung can prevent the formation of experimental pulmonary metastasis .
8-1	896-907	Furthermore	_	_	_	_
8-2	908-909	,	_	_	_	_
8-3	910-921	eosinophils	person|organization[50]	giv|new[50]	coref|coref	9-1|9-1
8-4	922-934	infiltration	organization[50]	new[50]	_	_
8-5	935-937	in	organization[50]	new[50]	_	_
8-6	938-941	the	organization[50]|object[51]	new[50]|new[51]	coref	16-23[0_51]
8-7	942-946	lung	organization[50]|object[51]	new[50]|new[51]	_	_
8-8	947-950	can	_	_	_	_
8-9	951-958	prevent	_	_	_	_
8-10	959-962	the	event[52]	new[52]	_	_
8-11	963-972	formation	event[52]	new[52]	_	_
8-12	973-975	of	event[52]	new[52]	_	_
8-13	976-988	experimental	event[52]|event[54]	new[52]|new[54]	coref	19-10[151_54]
8-14	989-998	pulmonary	event[52]|person|event[54]	new[52]|new|new[54]	_	_
8-15	999-1009	metastasis	event[52]|event[54]	new[52]|new[54]	_	_
8-16	1010-1011	.	_	_	_	_

#Text=Eosinophils are equipped with granules carrying a plethora of cytotoxic mediators , such as the cationic proteins major basic protein ( MBP ) , eosinophil cationic protein ( ECP ) , eosinophil peroxidase ( EPX ) , and granzymes ( granzyme-A in human cells , granzyme-B in murine cells ) that can destroy target cells or tissues .
9-1	1012-1023	Eosinophils	place	giv	coref	10-3
9-2	1024-1027	are	_	_	_	_
9-3	1028-1036	equipped	_	_	_	_
9-4	1037-1041	with	_	_	_	_
9-5	1042-1050	granules	object	new	coref	24-21[199_0]
9-6	1051-1059	carrying	_	_	_	_
9-7	1060-1061	a	abstract[57]	new[57]	_	_
9-8	1062-1070	plethora	abstract[57]	new[57]	_	_
9-9	1071-1073	of	abstract[57]	new[57]	_	_
9-10	1074-1083	cytotoxic	abstract[57]|person[58]	new[57]|new[58]	_	_
9-11	1084-1093	mediators	abstract[57]|person[58]	new[57]|new[58]	_	_
9-12	1094-1095	,	_	_	_	_
9-13	1096-1100	such	_	_	_	_
9-14	1101-1103	as	_	_	_	_
9-15	1104-1107	the	substance[59]|substance[60]	new[59]|new[60]	coref|coref	9-25[63_60]|9-25[63_60]
9-16	1108-1116	cationic	substance[59]|substance[60]	new[59]|new[60]	_	_
9-17	1117-1125	proteins	substance[59]|substance[60]	new[59]|new[60]	_	_
9-18	1126-1131	major	substance[60]	new[60]	_	_
9-19	1132-1137	basic	substance[60]	new[60]	_	_
9-20	1138-1145	protein	substance[60]	new[60]	_	_
9-21	1146-1147	(	_	_	_	_
9-22	1148-1151	MBP	object	new	_	_
9-23	1152-1153	)	_	_	_	_
9-24	1154-1155	,	_	_	_	_
9-25	1156-1166	eosinophil	substance[63]	giv[63]	coref	14-8[0_63]
9-26	1167-1175	cationic	abstract|substance[63]	new|giv[63]	_	_
9-27	1176-1183	protein	substance[63]	giv[63]	_	_
9-28	1184-1185	(	_	_	_	_
9-29	1186-1189	ECP	object	new	_	_
9-30	1190-1191	)	_	_	_	_
9-31	1192-1193	,	_	_	_	_
9-32	1194-1204	eosinophil	abstract|abstract[66]	new|new[66]	appos|appos	9-35[0_66]|9-35[0_66]
9-33	1205-1215	peroxidase	abstract[66]	new[66]	_	_
9-34	1216-1217	(	_	_	_	_
9-35	1218-1221	EPX	abstract	giv	_	_
9-36	1222-1223	)	_	_	_	_
9-37	1224-1225	,	_	_	_	_
9-38	1226-1229	and	_	_	_	_
9-39	1230-1239	granzymes	substance	new	_	_
9-40	1240-1241	(	_	_	_	_
9-41	1242-1252	granzyme-A	abstract[69]	new[69]	coref	10-16[0_69]
9-42	1253-1255	in	abstract[69]	new[69]	_	_
9-43	1256-1261	human	abstract[69]|object[70]	new[69]|giv[70]	coref	9-54[73_70]
9-44	1262-1267	cells	abstract[69]|object[70]	new[69]|giv[70]	_	_
9-45	1268-1269	,	abstract[69]|object[70]	new[69]|giv[70]	_	_
9-46	1270-1280	granzyme-B	abstract[69]|object[70]|abstract[71]	new[69]|giv[70]|new[71]	_	_
9-47	1281-1283	in	abstract[69]|object[70]|abstract[71]	new[69]|giv[70]|new[71]	_	_
9-48	1284-1290	murine	abstract[69]|object[70]|abstract[71]|substance	new[69]|giv[70]|new[71]|new	_	_
9-49	1291-1296	cells	abstract[69]|object[70]|abstract[71]	new[69]|giv[70]|new[71]	_	_
9-50	1297-1298	)	_	_	_	_
9-51	1299-1303	that	_	_	_	_
9-52	1304-1307	can	_	_	_	_
9-53	1308-1315	destroy	_	_	_	_
9-54	1316-1322	target	object[73]	giv[73]	coref	10-9[78_73]
9-55	1323-1328	cells	object[73]	giv[73]	_	_
9-56	1329-1331	or	object[73]	giv[73]	_	_
9-57	1332-1339	tissues	object[73]|object	giv[73]|giv	_	_
9-58	1340-1341	.	_	_	_	_

#Text=Indeed , eosinophils were shown to directly kill human colon carcinoma cells via release of granzyme-A in a mechanism dependent on the integrin CD11a/CD18 and on the cytokine IL-18 .
10-1	1342-1348	Indeed	_	_	_	_
10-2	1349-1350	,	_	_	_	_
10-3	1351-1362	eosinophils	abstract	giv	coref	11-4
10-4	1363-1367	were	_	_	_	_
10-5	1368-1373	shown	_	_	_	_
10-6	1374-1376	to	_	_	_	_
10-7	1377-1385	directly	_	_	_	_
10-8	1386-1390	kill	_	_	_	_
10-9	1391-1396	human	object[78]	giv[78]	coref	11-16[93_78]
10-10	1397-1402	colon	object|object[78]	new|giv[78]	_	_
10-11	1403-1412	carcinoma	object|object[78]	giv|giv[78]	_	_
10-12	1413-1418	cells	object[78]	giv[78]	_	_
10-13	1419-1422	via	_	_	_	_
10-14	1423-1430	release	event[79]	new[79]	_	_
10-15	1431-1433	of	event[79]	new[79]	_	_
10-16	1434-1444	granzyme-A	event[79]|abstract	new[79]|giv	_	_
10-17	1445-1447	in	_	_	_	_
10-18	1448-1449	a	abstract[81]	new[81]	_	_
10-19	1450-1459	mechanism	abstract[81]	new[81]	_	_
10-20	1460-1469	dependent	_	_	_	_
10-21	1470-1472	on	_	_	_	_
10-22	1473-1476	the	object[83]	new[83]	_	_
10-23	1477-1485	integrin	person|object[83]	new|new[83]	_	_
10-24	1486-1496	CD11a/CD18	object[83]	new[83]	_	_
10-25	1497-1500	and	_	_	_	_
10-26	1501-1503	on	_	_	_	_
10-27	1504-1507	the	place[85]	new[85]	_	_
10-28	1508-1516	cytokine	abstract|place[85]	new|new[85]	_	_
10-29	1517-1522	IL-18	place[85]	new[85]	_	_
10-30	1523-1524	.	_	_	_	_

#Text=In addition , eosinophils activated by cross-linking of the receptor 2B4/CD244 exhibited tumoricidal activities against human B lymphoma cells .
11-1	1525-1527	In	_	_	_	_
11-2	1528-1536	addition	_	_	_	_
11-3	1537-1538	,	_	_	_	_
11-4	1539-1550	eosinophils	substance	giv	coref	14-17
11-5	1551-1560	activated	_	_	_	_
11-6	1561-1563	by	_	_	_	_
11-7	1564-1577	cross-linking	abstract[87]	new[87]	_	_
11-8	1578-1580	of	abstract[87]	new[87]	_	_
11-9	1581-1584	the	abstract[87]|substance[88]	new[87]|new[88]	_	_
11-10	1585-1593	receptor	abstract[87]|substance[88]	new[87]|new[88]	_	_
11-11	1594-1603	2B4/CD244	abstract	new	_	_
11-12	1604-1613	exhibited	_	_	_	_
11-13	1614-1625	tumoricidal	abstract[90]	new[90]	coref	15-22[118_90]
11-14	1626-1636	activities	abstract[90]	new[90]	_	_
11-15	1637-1644	against	abstract[90]	new[90]	_	_
11-16	1645-1650	human	abstract[90]|object[93]	new[90]|giv[93]	coref	21-17[168_93]
11-17	1651-1652	B	abstract[90]|person|object[93]	new[90]|new|giv[93]	_	_
11-18	1653-1661	lymphoma	abstract[90]|abstract|object[93]	new[90]|new|giv[93]	_	_
11-19	1662-1667	cells	abstract[90]|object[93]	new[90]|giv[93]	_	_
11-20	1668-1669	.	_	_	_	_

#Text=It appears that the process of adhesion through integrins is important for eosinophil activation during inflammation .
12-1	1670-1672	It	_	_	_	_
12-2	1673-1680	appears	_	_	_	_
12-3	1681-1685	that	_	_	_	_
12-4	1686-1689	the	abstract[94]	new[94]	_	_
12-5	1690-1697	process	abstract[94]	new[94]	_	_
12-6	1698-1700	of	abstract[94]	new[94]	_	_
12-7	1701-1709	adhesion	abstract[94]|abstract	new[94]|new	coref	13-7[101_0]
12-8	1710-1717	through	abstract[94]	new[94]	_	_
12-9	1718-1727	integrins	abstract[94]|substance	new[94]|new	_	_
12-10	1728-1730	is	_	_	_	_
12-11	1731-1740	important	_	_	_	_
12-12	1741-1744	for	_	_	_	_
12-13	1745-1755	eosinophil	abstract[97]	new[97]	coref	22-13[0_97]
12-14	1756-1766	activation	abstract[97]	new[97]	_	_
12-15	1767-1773	during	_	_	_	_
12-16	1774-1786	inflammation	abstract	new	_	_
12-17	1787-1788	.	_	_	_	_

#Text=However , it is unclear whether cell adhesion and degranulation are sequential or independent events .
13-1	1789-1796	However	_	_	_	_
13-2	1797-1798	,	_	_	_	_
13-3	1799-1801	it	abstract	new	cata	13-3[0_103]
13-4	1802-1804	is	_	_	_	_
13-5	1805-1812	unclear	_	_	_	_
13-6	1813-1820	whether	abstract[103]	new[103]	_	_
13-7	1821-1825	cell	place|abstract[101]|abstract[103]	new|giv[101]|new[103]	coref|coref	23-7|23-7
13-8	1826-1834	adhesion	abstract[101]|abstract[103]	giv[101]|new[103]	_	_
13-9	1835-1838	and	abstract[103]	new[103]	_	_
13-10	1839-1852	degranulation	event|abstract[103]	new|new[103]	_	_
13-11	1853-1856	are	abstract[103]	new[103]	_	_
13-12	1857-1867	sequential	abstract[103]	new[103]	_	_
13-13	1868-1870	or	_	_	_	_
13-14	1871-1882	independent	_	_	_	_
13-15	1883-1889	events	event	new	_	_
13-16	1890-1891	.	_	_	_	_

#Text=In addition , the mechanisms of granule protein secretion ( i. e. , degranulation ) in eosinophils leading to tumor cytotoxicity remain to be defined .
14-1	1892-1894	In	_	_	_	_
14-2	1895-1903	addition	_	_	_	_
14-3	1904-1905	,	_	_	_	_
14-4	1906-1909	the	abstract[105]	new[105]	coref	22-6[172_105]
14-5	1910-1920	mechanisms	abstract[105]	new[105]	_	_
14-6	1921-1923	of	abstract[105]	new[105]	_	_
14-7	1924-1931	granule	abstract[105]|abstract[107]	new[105]|new[107]	appos	14-14[0_107]
14-8	1932-1939	protein	abstract[105]|substance|abstract[107]	new[105]|giv|new[107]	_	_
14-9	1940-1949	secretion	abstract[105]|abstract[107]	new[105]|new[107]	_	_
14-10	1950-1951	(	abstract[105]	new[105]	_	_
14-11	1952-1954	i.	abstract[105]	new[105]	_	_
14-12	1955-1957	e.	abstract[105]	new[105]	_	_
14-13	1958-1959	,	abstract[105]	new[105]	_	_
14-14	1960-1973	degranulation	abstract[105]|abstract	new[105]|giv	coref	24-18[198_0]
14-15	1974-1975	)	abstract[105]	new[105]	_	_
14-16	1976-1978	in	abstract[105]	new[105]	_	_
14-17	1979-1990	eosinophils	abstract[105]|substance	new[105]|giv	coref	17-6[135_0]
14-18	1991-1998	leading	_	_	_	_
14-19	1999-2001	to	_	_	_	_
14-20	2002-2007	tumor	abstract|abstract[111]	giv|new[111]	coref|coref	15-30|15-30
14-21	2008-2020	cytotoxicity	abstract[111]	new[111]	_	_
14-22	2021-2027	remain	_	_	_	_
14-23	2028-2030	to	_	_	_	_
14-24	2031-2033	be	_	_	_	_
14-25	2034-2041	defined	_	_	_	_
14-26	2042-2043	.	_	_	_	_

#Text=IL-33 is an epithelial-derived “ alarmin ” playing multiple functions in Th2-related immunopathologies and recently implied in cancer immunity , exerting pro- or anti-tumoral activities , depending on the tumor type and microenvironmental factors .
15-1	2044-2049	IL-33	object	new	coref	15-3[113_0]
15-2	2050-2052	is	_	_	_	_
15-3	2053-2055	an	object[113]	giv[113]	coref	16-7[0_113]
15-4	2056-2074	epithelial-derived	object[113]	giv[113]	_	_
15-5	2075-2076	“	object[113]	giv[113]	_	_
15-6	2077-2084	alarmin	object[113]	giv[113]	_	_
15-7	2085-2086	”	object[113]	giv[113]	_	_
15-8	2087-2094	playing	_	_	_	_
15-9	2095-2103	multiple	abstract[114]	new[114]	coref	23-15[181_114]
15-10	2104-2113	functions	abstract[114]	new[114]	_	_
15-11	2114-2116	in	_	_	_	_
15-12	2117-2128	Th2-related	abstract[115]	new[115]	_	_
15-13	2129-2146	immunopathologies	abstract[115]	new[115]	_	_
15-14	2147-2150	and	_	_	_	_
15-15	2151-2159	recently	_	_	_	_
15-16	2160-2167	implied	_	_	_	_
15-17	2168-2170	in	_	_	_	_
15-18	2171-2177	cancer	abstract|event[117]	giv|new[117]	coref|coref	16-25[132_0]|16-25[132_0]
15-19	2178-2186	immunity	event[117]	new[117]	_	_
15-20	2187-2188	,	_	_	_	_
15-21	2189-2197	exerting	_	_	_	_
15-22	2198-2202	pro-	abstract[118]	giv[118]	coref	24-7[194_118]
15-23	2203-2205	or	abstract[118]	giv[118]	_	_
15-24	2206-2218	anti-tumoral	abstract[118]	giv[118]	_	_
15-25	2219-2229	activities	abstract[118]	giv[118]	_	_
15-26	2230-2231	,	_	_	_	_
15-27	2232-2241	depending	_	_	_	_
15-28	2242-2244	on	_	_	_	_
15-29	2245-2248	the	abstract[120]	new[120]	_	_
15-30	2249-2254	tumor	abstract|abstract[120]	giv|new[120]	coref	16-1
15-31	2255-2259	type	abstract[120]	new[120]	_	_
15-32	2260-2263	and	_	_	_	_
15-33	2264-2282	microenvironmental	abstract[121]	new[121]	_	_
15-34	2283-2290	factors	abstract[121]	new[121]	_	_
15-35	2291-2292	.	_	_	_	_

#Text=Tumor over-expression or exogenous administration of IL-33 promotes anti-tumor immune responses in vivo in models of melanoma , acute myeloid leukemia , lung and colorectal cancer .
16-1	2293-2298	Tumor	abstract|organization[123]	giv|new[123]	coref|coref	19-7|19-7
16-2	2299-2314	over-expression	organization[123]	new[123]	_	_
16-3	2315-2317	or	organization[123]	new[123]	_	_
16-4	2318-2327	exogenous	organization[123]	new[123]	_	_
16-5	2328-2342	administration	organization[123]	new[123]	_	_
16-6	2343-2345	of	organization[123]	new[123]	_	_
16-7	2346-2351	IL-33	organization[123]|substance	new[123]|giv	coref	17-1
16-8	2352-2360	promotes	_	_	_	_
16-9	2361-2371	anti-tumor	abstract[126]	new[126]	_	_
16-10	2372-2378	immune	abstract|abstract[126]	new|new[126]	coref	23-42
16-11	2379-2388	responses	abstract[126]	new[126]	_	_
16-12	2389-2391	in	abstract[126]	new[126]	_	_
16-13	2392-2396	vivo	abstract[126]	new[126]	_	_
16-14	2397-2399	in	_	_	_	_
16-15	2400-2406	models	abstract[127]	new[127]	_	_
16-16	2407-2409	of	abstract[127]	new[127]	_	_
16-17	2410-2418	melanoma	abstract[127]|abstract	new[127]|giv	_	_
16-18	2419-2420	,	abstract[127]	new[127]	_	_
16-19	2421-2426	acute	abstract[127]|abstract[130]	new[127]|new[130]	_	_
16-20	2427-2434	myeloid	abstract[127]|place|abstract[130]	new[127]|new|new[130]	_	_
16-21	2435-2443	leukemia	abstract[127]|abstract[130]	new[127]|new[130]	_	_
16-22	2444-2445	,	abstract[127]	new[127]	_	_
16-23	2446-2450	lung	abstract[127]|object	new[127]|giv	coref	17-13[137_0]
16-24	2451-2454	and	abstract[127]	new[127]	_	_
16-25	2455-2465	colorectal	abstract[127]|abstract[132]	new[127]|giv[132]	coref	20-13[158_132]
16-26	2466-2472	cancer	abstract[127]|abstract[132]	new[127]|giv[132]	_	_
16-27	2473-2474	.	_	_	_	_

#Text=IL-33 drives substantial recruitment of eosinophils to inflamed sites , such as the lung , likely by promoting eosinophilopoiesis in the bone marrow .
17-1	2475-2480	IL-33	substance	giv	coref	18-4
17-2	2481-2487	drives	_	_	_	_
17-3	2488-2499	substantial	abstract[134]	new[134]	_	_
17-4	2500-2511	recruitment	abstract[134]	new[134]	_	_
17-5	2512-2514	of	abstract[134]	new[134]	_	_
17-6	2515-2526	eosinophils	abstract[134]|substance[135]	new[134]|giv[135]	coref	18-16[0_135]
17-7	2527-2529	to	abstract[134]|substance[135]	new[134]|giv[135]	_	_
17-8	2530-2538	inflamed	abstract[134]|substance[135]|place[136]	new[134]|giv[135]|new[136]	_	_
17-9	2539-2544	sites	abstract[134]|substance[135]|place[136]	new[134]|giv[135]|new[136]	_	_
17-10	2545-2546	,	abstract[134]|substance[135]|place[136]	new[134]|giv[135]|new[136]	_	_
17-11	2547-2551	such	abstract[134]|substance[135]|place[136]	new[134]|giv[135]|new[136]	_	_
17-12	2552-2554	as	abstract[134]|substance[135]|place[136]	new[134]|giv[135]|new[136]	_	_
17-13	2555-2558	the	abstract[134]|substance[135]|place[136]|object[137]	new[134]|giv[135]|new[136]|giv[137]	_	_
17-14	2559-2563	lung	abstract[134]|substance[135]|place[136]|object[137]	new[134]|giv[135]|new[136]|giv[137]	_	_
17-15	2564-2565	,	abstract[134]|substance[135]|place[136]|object[137]	new[134]|giv[135]|new[136]|giv[137]	_	_
17-16	2566-2572	likely	abstract[134]|substance[135]|place[136]|object[137]	new[134]|giv[135]|new[136]|giv[137]	_	_
17-17	2573-2575	by	_	_	_	_
17-18	2576-2585	promoting	_	_	_	_
17-19	2586-2604	eosinophilopoiesis	abstract[138]	new[138]	_	_
17-20	2605-2607	in	abstract[138]	new[138]	_	_
17-21	2608-2611	the	abstract[138]|animal[140]	new[138]|giv[140]	_	_
17-22	2612-2616	bone	abstract[138]|object|animal[140]	new[138]|giv|giv[140]	_	_
17-23	2617-2623	marrow	abstract[138]|animal[140]	new[138]|giv[140]	_	_
17-24	2624-2625	.	_	_	_	_

#Text=In addition , IL-33 can induce eosinophil superoxide anion production and promote the survival of eosinophils .
18-1	2626-2628	In	_	_	_	_
18-2	2629-2637	addition	_	_	_	_
18-3	2638-2639	,	_	_	_	_
18-4	2640-2645	IL-33	substance	giv	coref	19-5
18-5	2646-2649	can	_	_	_	_
18-6	2650-2656	induce	_	_	_	_
18-7	2657-2667	eosinophil	abstract[144]	new[144]	_	_
18-8	2668-2678	superoxide	substance|abstract[144]	new|new[144]	_	_
18-9	2679-2684	anion	object|abstract[144]	new|new[144]	_	_
18-10	2685-2695	production	abstract[144]	new[144]	_	_
18-11	2696-2699	and	_	_	_	_
18-12	2700-2707	promote	_	_	_	_
18-13	2708-2711	the	event[145]	new[145]	_	_
18-14	2712-2720	survival	event[145]	new[145]	_	_
18-15	2721-2723	of	event[145]	new[145]	_	_
18-16	2724-2735	eosinophils	event[145]|substance	new[145]|giv	coref	21-5
18-17	2736-2737	.	_	_	_	_

#Text=We initially reported that IL-33 inhibits tumor growth and pulmonary metastasis in vivo in an eosinophil-dependent manner .
19-1	2738-2740	We	person	acc	ana	21-1
19-2	2741-2750	initially	_	_	_	_
19-3	2751-2759	reported	_	_	_	_
19-4	2760-2764	that	_	_	_	_
19-5	2765-2770	IL-33	substance	giv	coref	20-8
19-6	2771-2779	inhibits	_	_	_	_
19-7	2780-2785	tumor	abstract|abstract[150]	giv|giv[150]	coref|coref	24-24|24-24
19-8	2786-2792	growth	abstract[150]	giv[150]	_	_
19-9	2793-2796	and	_	_	_	_
19-10	2797-2806	pulmonary	event[151]	giv[151]	_	_
19-11	2807-2817	metastasis	event[151]	giv[151]	_	_
19-12	2818-2820	in	event[151]	giv[151]	_	_
19-13	2821-2825	vivo	event[151]	giv[151]	_	_
19-14	2826-2828	in	_	_	_	_
19-15	2829-2831	an	abstract[152]	new[152]	coref	23-25[184_152]
19-16	2832-2852	eosinophil-dependent	abstract[152]	new[152]	_	_
19-17	2853-2859	manner	abstract[152]	new[152]	_	_
19-18	2860-2861	.	_	_	_	_

#Text=Subsequent studies confirmed eosinophil-mediated anti-tumoral effects of IL-33 in pre-clinical models of metastatic peritoneal cancer , hepatocellular , and prostatic cancer .
20-1	2862-2872	Subsequent	abstract[153]	new[153]	_	_
20-2	2873-2880	studies	abstract[153]	new[153]	_	_
20-3	2881-2890	confirmed	_	_	_	_
20-4	2891-2910	eosinophil-mediated	abstract[154]	new[154]	_	_
20-5	2911-2923	anti-tumoral	abstract[154]	new[154]	_	_
20-6	2924-2931	effects	abstract[154]	new[154]	_	_
20-7	2932-2934	of	abstract[154]	new[154]	_	_
20-8	2935-2940	IL-33	abstract[154]|substance	new[154]|giv	coref	21-8
20-9	2941-2943	in	abstract[154]	new[154]	_	_
20-10	2944-2956	pre-clinical	abstract[154]|abstract[156]	new[154]|new[156]	_	_
20-11	2957-2963	models	abstract[154]|abstract[156]	new[154]|new[156]	_	_
20-12	2964-2966	of	abstract[154]|abstract[156]	new[154]|new[156]	_	_
20-13	2967-2977	metastatic	abstract[154]|abstract[156]|abstract[158]	new[154]|new[156]|giv[158]	coref	20-20[160_158]
20-14	2978-2988	peritoneal	abstract[154]|abstract[156]|place|abstract[158]	new[154]|new[156]|new|giv[158]	_	_
20-15	2989-2995	cancer	abstract[154]|abstract[156]|abstract[158]	new[154]|new[156]|giv[158]	_	_
20-16	2996-2997	,	abstract[154]|abstract[156]	new[154]|new[156]	_	_
20-17	2998-3012	hepatocellular	abstract[154]|abstract[156]|abstract	new[154]|new[156]|giv	_	_
20-18	3013-3014	,	abstract[154]|abstract[156]	new[154]|new[156]	_	_
20-19	3015-3018	and	abstract[154]|abstract[156]	new[154]|new[156]	_	_
20-20	3019-3028	prostatic	abstract[154]|abstract[156]|abstract[160]	new[154]|new[156]|giv[160]	_	_
20-21	3029-3035	cancer	abstract[154]|abstract[156]|abstract[160]	new[154]|new[156]|giv[160]	_	_
20-22	3036-3037	.	_	_	_	_

#Text=Our study suggested that eosinophils recruited by IL-33 might either function as accessory cells attracting CD8 T cells or play a direct antitumor role .
21-1	3038-3041	Our	person|abstract[162]	giv|new[162]	ana|ana	22-3|22-3
21-2	3042-3047	study	abstract[162]	new[162]	_	_
21-3	3048-3057	suggested	_	_	_	_
21-4	3058-3062	that	_	_	_	_
21-5	3063-3074	eosinophils	substance	giv	coref	22-11
21-6	3075-3084	recruited	_	_	_	_
21-7	3085-3087	by	_	_	_	_
21-8	3088-3093	IL-33	substance	giv	coref	22-15
21-9	3094-3099	might	_	_	_	_
21-10	3100-3106	either	abstract[165]	new[165]	_	_
21-11	3107-3115	function	abstract[165]	new[165]	_	_
21-12	3116-3118	as	abstract[165]	new[165]	_	_
21-13	3119-3128	accessory	abstract[165]	new[165]	_	_
21-14	3129-3134	cells	abstract[165]	new[165]	_	_
21-15	3135-3145	attracting	_	_	_	_
21-16	3146-3149	CD8	quantity	new	_	_
21-17	3150-3151	T	person|object[168]	new|giv[168]	coref|coref	24-23[201_168]|24-23[201_168]
21-18	3152-3157	cells	object[168]	giv[168]	_	_
21-19	3158-3160	or	_	_	_	_
21-20	3161-3165	play	_	_	_	_
21-21	3166-3167	a	abstract[170]	giv[170]	_	_
21-22	3168-3174	direct	abstract[170]	giv[170]	_	_
21-23	3175-3184	antitumor	abstract|abstract[170]	new|giv[170]	_	_
21-24	3185-3189	role	abstract[170]	giv[170]	_	_
21-25	3190-3191	.	_	_	_	_

#Text=Here , we further investigated the anti-tumoral mechanisms operated by eosinophils following activation with IL-33 .
22-1	3192-3196	Here	_	_	_	_
22-2	3197-3198	,	_	_	_	_
22-3	3199-3201	we	person	giv	ana	23-10
22-4	3202-3209	further	_	_	_	_
22-5	3210-3222	investigated	_	_	_	_
22-6	3223-3226	the	abstract[172]	giv[172]	_	_
22-7	3227-3239	anti-tumoral	abstract[172]	giv[172]	_	_
22-8	3240-3250	mechanisms	abstract[172]	giv[172]	_	_
22-9	3251-3259	operated	_	_	_	_
22-10	3260-3262	by	_	_	_	_
22-11	3263-3274	eosinophils	substance	giv	coref	23-18[182_0]
22-12	3275-3284	following	_	_	_	_
22-13	3285-3295	activation	abstract	giv	_	_
22-14	3296-3300	with	_	_	_	_
22-15	3301-3306	IL-33	substance	giv	coref	23-13
22-16	3307-3308	.	_	_	_	_

#Text=By using a panel of tumor cell lines , we show that IL-33 promotes tumoricidal functions of eosinophils in vitro and in vivo in a cell adhesion-dependent manner , through the integrin CD11b/CD18 and by inducing lytic granule convergence to the immune synapse .
23-1	3309-3311	By	_	_	_	_
23-2	3312-3317	using	_	_	_	_
23-3	3318-3319	a	object[176]	new[176]	_	_
23-4	3320-3325	panel	object[176]	new[176]	_	_
23-5	3326-3328	of	object[176]	new[176]	_	_
23-6	3329-3334	tumor	object[176]|object[178]	new[176]|new[178]	_	_
23-7	3335-3339	cell	object[176]|place|object[178]	new[176]|giv|new[178]	coref	23-26
23-8	3340-3345	lines	object[176]|object[178]	new[176]|new[178]	_	_
23-9	3346-3347	,	_	_	_	_
23-10	3348-3350	we	person	giv	ana	24-1
23-11	3351-3355	show	_	_	_	_
23-12	3356-3360	that	_	_	_	_
23-13	3361-3366	IL-33	abstract	giv	coref	24-12
23-14	3367-3375	promotes	_	_	_	_
23-15	3376-3387	tumoricidal	abstract[181]	giv[181]	_	_
23-16	3388-3397	functions	abstract[181]	giv[181]	_	_
23-17	3398-3400	of	abstract[181]	giv[181]	_	_
23-18	3401-3412	eosinophils	abstract[181]|substance[182]	giv[181]|giv[182]	_	_
23-19	3413-3415	in	abstract[181]|substance[182]	giv[181]|giv[182]	_	_
23-20	3416-3421	vitro	abstract[181]|substance[182]	giv[181]|giv[182]	_	_
23-21	3422-3425	and	_	_	_	_
23-22	3426-3428	in	_	_	_	_
23-23	3429-3433	vivo	_	_	_	_
23-24	3434-3436	in	_	_	_	_
23-25	3437-3438	a	abstract[184]	giv[184]	_	_
23-26	3439-3443	cell	place|abstract[184]	giv|giv[184]	coref	24-15
23-27	3444-3462	adhesion-dependent	abstract[184]	giv[184]	_	_
23-28	3463-3469	manner	abstract[184]	giv[184]	_	_
23-29	3470-3471	,	abstract[184]	giv[184]	_	_
23-30	3472-3479	through	abstract[184]	giv[184]	_	_
23-31	3480-3483	the	abstract[184]|object[185]	giv[184]|new[185]	_	_
23-32	3484-3492	integrin	abstract[184]|object[185]	giv[184]|new[185]	_	_
23-33	3493-3503	CD11b/CD18	abstract[184]|object[185]	giv[184]|new[185]	_	_
23-34	3504-3507	and	_	_	_	_
23-35	3508-3510	by	_	_	_	_
23-36	3511-3519	inducing	_	_	_	_
23-37	3520-3525	lytic	event[187]	new[187]	_	_
23-38	3526-3533	granule	abstract|event[187]	new|new[187]	_	_
23-39	3534-3545	convergence	event[187]	new[187]	_	_
23-40	3546-3548	to	event[187]	new[187]	_	_
23-41	3549-3552	the	event[187]|place[189]	new[187]|new[189]	_	_
23-42	3553-3559	immune	event[187]|abstract|place[189]	new[187]|giv|new[189]	_	_
23-43	3560-3567	synapse	event[187]|place[189]	new[187]|new[189]	_	_
23-44	3568-3569	.	_	_	_	_

#Text=Our data provide mechanistic insights into eosinophil anti-tumor activities stimulated by IL-33 that involve cell contact and directional secretion of granules toward target tumor cells enhancing killing efficiency .
24-1	3570-3573	Our	person|abstract[191]	giv|new[191]	_	_
24-2	3574-3578	data	abstract[191]	new[191]	_	_
24-3	3579-3586	provide	_	_	_	_
24-4	3587-3598	mechanistic	abstract[192]	new[192]	_	_
24-5	3599-3607	insights	abstract[192]	new[192]	_	_
24-6	3608-3612	into	abstract[192]	new[192]	_	_
24-7	3613-3623	eosinophil	abstract[192]|abstract[194]	new[192]|giv[194]	_	_
24-8	3624-3634	anti-tumor	abstract[192]|abstract|abstract[194]	new[192]|new|giv[194]	_	_
24-9	3635-3645	activities	abstract[192]|abstract[194]	new[192]|giv[194]	_	_
24-10	3646-3656	stimulated	_	_	_	_
24-11	3657-3659	by	_	_	_	_
24-12	3660-3665	IL-33	substance	giv	_	_
24-13	3666-3670	that	_	_	_	_
24-14	3671-3678	involve	_	_	_	_
24-15	3679-3683	cell	object|abstract[197]	giv|new[197]	_	_
24-16	3684-3691	contact	abstract[197]	new[197]	_	_
24-17	3692-3695	and	_	_	_	_
24-18	3696-3707	directional	abstract[198]	giv[198]	_	_
24-19	3708-3717	secretion	abstract[198]	giv[198]	_	_
24-20	3718-3720	of	abstract[198]	giv[198]	_	_
24-21	3721-3729	granules	abstract[198]|object[199]	giv[198]|giv[199]	_	_
24-22	3730-3736	toward	abstract[198]|object[199]	giv[198]|giv[199]	_	_
24-23	3737-3743	target	abstract[198]|object[199]|object[201]	giv[198]|giv[199]|giv[201]	_	_
24-24	3744-3749	tumor	abstract[198]|object[199]|abstract|object[201]	giv[198]|giv[199]|giv|giv[201]	_	_
24-25	3750-3755	cells	abstract[198]|object[199]|object[201]	giv[198]|giv[199]|giv[201]	_	_
24-26	3756-3765	enhancing	_	_	_	_
24-27	3766-3773	killing	_	_	_	_
24-28	3774-3784	efficiency	abstract	new	_	_
24-29	3785-3786	.	_	_	_	_
